Stock Price Quote

VENUS REMEDIES LTD.

NSE : VENUSREMBSE : 526953ISIN CODE : INE411B01019Industry : Pharmaceuticals & DrugsHouse : Private
BSE328.00-2 (-0.61 %)
PREV CLOSE ( ) 330.00
OPEN PRICE ( ) 330.70
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2847
TODAY'S LOW / HIGH ( )327.40 333.75
52 WK LOW / HIGH ( )185.65 429.6
NSE328.20-1.5 (-0.45 %)
PREV CLOSE( ) 329.70
OPEN PRICE ( ) 328.45
BID PRICE (QTY) 328.20 (286)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 18520
TODAY'S LOW / HIGH( ) 327.75 334.65
52 WK LOW / HIGH ( )188.6 430
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1989
Management Info
Pawan Chaudhary - Chairman Pawan Chaudhary - Managing Director
Registered Office

Address S. C. O. 857, C. No. 10,2nd Floor,N A C Manimajra,
Chandigarh,
Chandigarh-160101

Phone 0172-2561244/5577

Email info@venusremedies.com

Website www.venusremedies.com / www.vmrcindia.com

Registrars Details
Link Intime India Pvt Ltd.
Noble Heights, 1st Floor, Plot NH 2,C-1 Block LSC, Near Savitri Market,Janakpuri,New Delhi
Listing : BSE, NSE, MCX

NEWS

01Apr Venus Remedies informs about disclosure
Venus Remedies has informed that it has been awarded with Rs 2.50 crore..
19Mar Lemon Tree Hotels, Swan Energy and Ven
Lemon Tree Hotels has signed new property -- Lemon Tree Hotels, Agartala..
19Mar Venus Remedies rises on getting market
Venus Remedies is currently trading at Rs. 327.55, up by 2.10 points or..
18Mar Venus Remedies gets marketing authoris
Venus Remedies has expanded the reach of its oncology drugs in the Asia..
12Mar Rail Vikas Nigam, NBCC and Mankind Pha
Rail Vikas Nigam has emerged as the Lowest Bidder (L1) from Central Rail..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit81.9289.6
Gross Profit 91.2 403.3
Operating Profit 154.2717
Net Sales 1312.35376.6

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Dr. Reddy's Lab (BSE)
peergroup  6217.15 (4.47%)
M.Cap ( in Cr)103713.42
Abbott India (BSE)
peergroup  25725.00 (1.03%)
M.Cap ( in Cr)54663.83
Bharat Parenterals (BSE)
peergroup  1701.80 (10.00%)
M.Cap ( in Cr)990.39
Alkem Laboratories (BSE)
peergroup  4857.90 (3.10%)
M.Cap ( in Cr)58083.48
NGL Fine-Chem (BSE)
peergroup  2711.85 (3.47%)
M.Cap ( in Cr)1675.39

Shareholding Pattern

NON-INSTITUTION 56.76%
PROMOTERS 41.76%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Venus Remedies Ltd.

Venus Remedies Ltd. was incorporated in the year 1989. Its today's share price is 328. Its current market capitalisation stands at Rs 438.44 Cr. In the latest quarter, company has reported Gross Sales of Rs. 5376.62 Cr and Total Income of Rs.5478.36 Cr. The company's management includes Neha Kodan, Akshansh Chaudhary, Ashutosh Jain, NPS Monga, Savita Gupta, Navdeep Sud, S K Chadha, Gilbert Wenzel, Peeyush Jain, Manu Chaudhary, Pawan Chaudhary, Pawan Chaudhary.

It is listed on the BSE with a BSE Code of 526953 , NSE with an NSE Symbol of VENUSREM and ISIN of INE411B01019. It's Registered office is at S. C. O. 857, C. No. 10,2nd Floor,N A C ManimajraChandigarh-160101, Chandigarh. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are JK Jain & Associates, Prem Garg & Associates, Vinod Kumar & Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.